<DOC>
	<DOCNO>NCT00208234</DOCNO>
	<brief_summary>The purpose study determine Xolair reduce abnormal increase limitation airflow patient asthma relatively short time period . Another purpose determine Xolair decrease amount inflammation lung asthmatic patient time period .</brief_summary>
	<brief_title>Effect Xolair Airway Hyperresponsiveness</brief_title>
	<detailed_description>Xolair , recombinant humanize monoclonal anti-IgE antibody , study extensively proven efficacious treatment asthma allergic disorder . In moderate severe allergic asthmatic patient , Xolair reduce asthma exacerbation improve symptom . However , limited data effect Xolair airway hyperreactivity , important component asthma .</detailed_description>
	<mesh_term>Respiratory Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Female patient must negative urine pregnancy test Visit 1 negative urine pregnancy test subsequent visit . In addition , female patient must use medically acceptable form birth control . History mild moderate asthma A positive skin prick test one perennial environmental allergen ( dog , cat , dermatophagoides farinae , dermatophagoides pteronyssinus ) A PC20 value methacholine &lt; 5 mg/mL A PC15 value hypertonic saline &lt; 4 minute Capable faithfully attend regularly schedule study visit Willing avoid prohibit medication period indicate protocol A baseline serum IgE level &gt; 30 IU/mL &lt; 700 IU/mL Women childbearing potential use medically acceptable form birth control , well woman breastfeed Known sensitivity study drug class study drug Any sinus , middle ear , oropharyngeal , upper low respiratory tract infection resolve least 2 week prior screen visit , antibiotic therapy complete least 2 week prior screen visit Patients history severe anaphylactoid anaphylactic reaction Patients take betaadrenergic antagonist form Patients previously expose Xolair Patients know hypersensitivity trial drug excipient ingredient related drug Chronic intermittent use inhale , oral , intranasal , intramuscular , intravenous corticosteroid , use topical corticosteroid intermittent use low potency preparation Use immunosuppressive medication History presence significant renal , hepatic , neurologic , cardiovascular , hematologic , metabolic , cerebrovascular , respiratory , gastrointestinal , significant medical condition , include autoimmune collagen vascular disorder aside organspecific autoimmune disease limit thyroid investigator 's opinion could interfere study require medical treatment would interfere study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>asthma</keyword>
</DOC>